Cargando…

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

SARS-CoV-2 501Y.V2 (B.1.351), a novel lineage of coronavirus causing COVID-19, contains substitutions in two immunodominant domains of the spike protein. Here, we show that pseudovirus expressing 501Y.V2 spike protein completely escapes three classes of therapeutically relevant antibodies. This pseu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wibmer, Constantinos Kurt, Ayres, Frances, Hermanus, Tandile, Madzivhandila, Mashudu, Kgagudi, Prudence, Oosthuysen, Brent, Lambson, Bronwen E., de Oliveira, Tulio, Vermeulen, Marion, van der Berg, Karin, Rossouw, Theresa, Boswell, Michael, Ueckermann, Veronica, Meiring, Susan, von Gottberg, Anne, Cohen, Cheryl, Morris, Lynn, Bhiman, Jinal N., Moore, Penny L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836116/ https://www.ncbi.nlm.nih.gov/pubmed/33501446 http://dx.doi.org/10.1101/2021.01.18.427166

Ejemplares similares

SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies
por: Moyo-Gwete, Thandeka, et al.
Publicado: (2021)

Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351)
por: Moyo-Gwete, Thandeka, et al.
Publicado: (2021)

501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro
por: Liu, Haolin, et al.
Publicado: (2021)

Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants
por: Moyo-Gwete, Thandeka, et al.
Publicado: (2022)

Characterization of SARS-CoV-2 Variants N501Y.V1 and N501Y.V2 Spike on Viral Infectivity
por: Tang, Haijun, et al.
Publicado: (2021)

Corrigendum: Characterization of SARS-CoV-2 Variants N501Y.V1 and N501Y.V2 Spike on Viral Infectivity
por: Tang, Haijun, et al.
Publicado: (2021)

Live Virus Neutralisation of the 501Y.V1 and 501Y.V2 SARS-CoV-2 Variants following INO-4800 Vaccination of Ferrets
por: Riddell, Shane, et al.
Publicado: (2021)

Increased elastase sensitivity and decreased intramolecular interactions in the more transmissible 501Y.V1 and 501Y.V2 SARS-CoV-2 variants’ spike protein–an in silico analysis
por: Pokhrel, Suman, et al.
Publicado: (2021)

Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination
por: Motsoeneng, Boitumelo M., et al.
Publicado: (2023)

501Y.V2 spike protein resists the neutralizing antibody in atomistic simulations
por: Ngo, Son Tung
Publicado: (2022)

The 501Y.V2 SARS-CoV-2 variant has an intermediate viral load between the 501Y.V1 and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients
por: Teyssou, Elisa, et al.
Publicado: (2021)

The basis of a more contagious 501Y.V1 variant of SARS-CoV-2
por: Liu, Haolin, et al.
Publicado: (2021)

Thermodynamics and kinetics in antibody resistance of the 501Y.V2 SARS-CoV-2 variant
por: Ngo, Son Tung, et al.
Publicado: (2021)

Introduction of the South African SARS-CoV-2 variant 501Y.V2 into the UK
por: Tang, Julian W., et al.
Publicado: (2021)

Antibody-dependent cellular cytotoxicity against SARS-CoV-2 Omicron sub-lineages is reduced in convalescent sera regardless of infecting variant
por: Richardson, Simone I., et al.
Publicado: (2022)

Live virus neutralization testing in convalescent patients and subjects vaccinated against 19A, 20B, 20I/501Y.V1 and 20H/501Y.V2 isolates of SARS-CoV-2
por: Saade, Carla, et al.
Publicado: (2021)

Detection of SARS-CoV-2 variant 501Y.V2 in Comoros Islands in January 2021
por: N. Agoti, Charles, et al.
Publicado: (2021)

Preliminary data on severe SARS-CoV-2 infection caused by the 501Y.V2 variant
por: Louis, Guillaume, et al.
Publicado: (2021)

Serum sample neutralisation of BBIBP-CorV and ZF2001 vaccines to SARS-CoV-2 501Y.V2
por: Huang, Baoying, et al.
Publicado: (2021)

SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape
por: Li, Qianqian, et al.
Publicado: (2021)

Efficiency of transmission-based precautions (TBPs) against SARS-CoV-2 501Y.V2 variant transmissibility in the ICU
por: Schortgen, Frédérique, et al.
Publicado: (2021)

Introduction of SARS-CoV-2 variant of concern 20h/501Y.V2 (B.1.351) from Malawi to Italy
por: Novazzi, Federica, et al.
Publicado: (2021)

Genome Sequence of a SARS-CoV-2 P.1 Variant of Concern (20J/501Y.V3) from Bangladesh
por: Sarkar, M. Murshed Hasan, et al.
Publicado: (2021)

Imported SARS-CoV-2 V501Y.V2 variant (B.1.351) detected in travelers from South Africa and Tanzania to India
por: Yadav, Pragya D., et al.
Publicado: (2021)

Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages
por: Bhiman, Jinal N., et al.
Publicado: (2023)

SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals
por: Richardson, Simone I., et al.
Publicado: (2022)

Possible Role of Accessory Proteins in the Viral Replication for the 20I/501Y.V1 (B.1.1.7) SARS CoV-2 Variant
por: Nyayanit, Dimpal A., et al.
Publicado: (2021)

Prognosis of patients with acute respiratory failure due to the SARS-CoV-2 501Y.V2 variant: a multicenter retrospective matched cohort study
por: Puech, Bérénice, et al.
Publicado: (2022)

Dependence on a variable residue limits the breadth of an HIV MPER neutralizing antibody, despite convergent evolution with broadly neutralizing antibodies
por: Scheepers, Cathrine, et al.
Publicado: (2022)

Development of a multiplex RT-qPCR using the drop out strategy to screen the SARS-CoV-2 South African 501Y.V2 variant
por: Maclot, François, et al.
Publicado: (2021)

Outbreak of SARS-CoV-2 Lineage 20I/501Y.V1 in a Nursing Home Underlines the Crucial Role of Vaccination in Both Residents and Staff
por: Orsi, Andrea, et al.
Publicado: (2021)

V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity
por: van Eeden, Charmaine, et al.
Publicado: (2018)

Replicative Fitness of a SARS-CoV-2 20I/501Y.V1 Variant from Lineage B.1.1.7 in Human Reconstituted Bronchial Epithelium
por: Touret, Franck, et al.
Publicado: (2021)

Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern
por: Kitchin, Dale, et al.
Publicado: (2022)

Characteristics and outcomes of SARS-COV 2 critically ill patients after emergence of the variant of concern 20H/501Y.V2: A comparative cohort study
por: Aries, Philippe, et al.
Publicado: (2022)

HIV Broadly Neutralizing Antibodies Expressed as IgG3 Preserve Neutralization Potency and Show Improved Fc Effector Function
por: Richardson, Simone I., et al.
Publicado: (2021)

In Silico Investigation of the New UK (B.1.1.7) and South African (501Y.V2) SARS-CoV-2 Variants with a Focus at the ACE2–Spike RBD Interface
por: Villoutreix, Bruno O., et al.
Publicado: (2021)

Synergistic infection of BrYV and PEMV 2 increases the accumulations of both BrYV and BrYV-derived siRNAs in Nicotiana benthamiana
por: Zhou, Cui-Ji, et al.
Publicado: (2017)

Emergence and phenotypic characterization of the global SARS-CoV-2 C.1.2 lineage
por: Scheepers, Cathrine, et al.
Publicado: (2022)

Early assessment of diffusion and possible expansion of SARS-CoV-2 Lineage 20I/501Y.V1 (B.1.1.7, variant of concern 202012/01) in France, January to March 2021
por: Gaymard, Alexandre, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8cvg0gl3us00tm074u557c3gro